Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Serotonin precursor effects in tardive dyskinesia.

H A Nasrallah, R E Smith, F J Dunner

    Psychopharmacology
    |January 1, 1982
    PubMed
    Summary

    Serotonin precursors like 5-hydroxytryptophan (5HTP) did not improve tardive dyskinesia symptoms in a small study. Some patients experienced worsened psychotic symptoms, suggesting serotonin

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Impact of desertification on temperature trends in the Middle East.

    Environmental monitoring and assessment·2013
    Same author

    Renaming schizophrenia: keeping up with the facts.

    Schizophrenia research·2013
    Same author

    Persistent infection with neurotropic herpes viruses and cognitive impairment.

    Psychological medicine·2012
    Same author

    Protection from olanzapine-induced metabolic toxicity in mice by acetaminophen and tetrahydroindenoindole.

    International journal of obesity (2005)·2010
    Same author

    Linkage analysis of schizophrenia in African-American families.

    Schizophrenia research·2009
    Same author

    Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles.

    Molecular psychiatry·2007

    Area of Science:

    • Neuroscience
    • Psychopharmacology
    • Movement Disorders

    Background:

    • Tardive dyskinesia (TD) is a movement disorder often associated with long-term antipsychotic use.
    • The role of serotoninergic systems in TD pathophysiology remains unclear.
    • Investigating neurotransmitter precursors offers insights into potential therapeutic targets.

    Purpose of the Study:

    • To investigate the efficacy of serotonin precursor supplementation in treating tardive dyskinesia.
    • To explore the role of serotonin in the neurobiology of tardive dyskinesia.

    Main Methods:

    • A double-blind, placebo-controlled crossover study was conducted.
    • Seven patients with established tardive dyskinesia received 5-hydroxytryptophan (5HTP) with carbidopa.
    • Outcomes measured included changes in dyskinetic movements and psychotic symptoms.

    Main Results:

    • Five patients completed the study.
    • No significant improvement in tardive dyskinesia movements was observed.
    • A majority of patients experienced exacerbation of psychotic symptoms.

    Conclusions:

    • Serotonin precursors, such as 5HTP, do not appear to offer therapeutic benefits for tardive dyskinesia.
    • The findings suggest a complex role for serotonin in TD, potentially involving the worsening of psychiatric symptoms.
    • Further research is needed to elucidate the precise involvement of serotoninergic pathways in tardive dyskinesia.

    Related Experiment Videos